Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion

Cancer Journal from Scientific American

Volumn 2, Issue 5, 1996, Pages 263-272

  Dadmarz, Roya D ^a   Ordoubadi, Aida ^a   Mixon, Arnold ^a   Thompson, Carolyn O ^a   Barracchini, Kathleen C ^a   Hijazi, Yasmine M ^a   Steller, Michael A ^a   Rosenberg, Steven A ^a   Schwartzentruber, Douglas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytokines; Human; MHC; T lymphocytes; TAL; TIL; Tumor immunity

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CYTOTOXICITY; FEMALE; HUMAN; IMMUNOLOGY; OVARY TUMOR; SECRETION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0000052318     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Freedman RS, Edwards CL, Kavanagh JJ et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother 1994;16:198-210.
2. Aoki Y, Takakuwa K, Kodama S et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991;51:1934-1939.
3. Ikarashi H, Fujita K, Takakuwa K et al. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Cancer Res 1994;54:190-196.
4. Freedman RS, Tomasovic B, Templin S et al. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Meth 1994;167:145-160.
5. Li WY, Lusheng S, Kanbour A, Herberman RB, Whiteside TL. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor a and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Cancer Res 1989;49:5979-5985.
6. Heo DS, Whiteside TL, Kanbour A, Herberman RB. Lymphocytes infiltrating human ovarian tumors. J Immunol 1988; 140: 4042-4049.
7. Lotzová E, Savary CA, Freedman RS, Edwards CL, Morris M. Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and pheno-type. Cancer Immunol Immunother 1990;31:169-175.
8. Apiranthitou-Drogari M, Paganin C, Bernasconi S et al. In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma. Cancer Immunol Immunother 1992; 35:289-295.
9. Ioannides CG, Rashed S, Fisk B, Fan D, Itoh K, Freedman RS. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and selective increase in CD8+ T cells by TNF-α. Lymphokine Cytokine Res 1991;10:307-315.
10. Vaccarello L, Wang YL, Whiteside TL. Sustained outgrowth of autotumor-reactive T lymphocytes from human ovarian carcinomas in the presence of tumor necrosis factor α and interleukin 2. Hum Immunol 1990;28:216-227.
11. Ioannides CG, Fisk B, Tomasovic B, Pandita R, Aggarwal BB, Freedman RS. Induction of interleukin-2 receptor by tumor necrosis factor α on cultured ovarian tumor-associated lymphocytes. Cancer Immunol Immunother 1992;35:83-91.
12. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991;51:4257-4265.
13. Peoples GE, Goedegebuure PS, Andrews JVR, Schoof DE, Eberlein TJ. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 1993;151:5481-5491.
14. Peoples GE, Schoof DD, Andrews JVR, Goedegebuure PS, Eberlein TJ. T-cell recognition of ovarian cancer. Surgery 1993; 114:227-234.
15. Ioannides CG, Freedman RS, Platsoucas CD, Rashed S, Kim YP. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 1991;146:1700-1707.
16. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Wharton JT, Freedman RS. Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. Scand J Immunol 1993;37:413-424.
17. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu protooncogene. Cell Immunol 1993;151:225-234.
18. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432-436.
19. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immundominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-2117.
20. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor-infiltrating lymphocytes for use in immunotherapy trials. J Immunol Meth 1987;102:127-141.
21. Schoof DD, Selleck CM, Massaro AF, Jung S-E, Eberlein TJ. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Cancer Res 1990; 50:1138-1143.
22. Morecki S, Topalian SL, Myers WW, Okrongly D, Okarma TB, Rosenberg SA. Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks. J Biol Response Mod 1990;9:463-474.
23. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142:3714-3725.
24. Hopkins KA. ASHI Laboratory Manual. 3rd ed. New York: American Society for Histocompatibility and Immunogenetics, 1994:I.B.1.5-I.B.1.6.
25. Moraes ME, Fernandez-Viña M, Stastny P. DNA typing for class II HLA antigens with allele-specific or group-specific amplification. V. Typing for alleles of the HLA-DR2 group. Hum Immunol 1991;31:139-144.
26. Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991;146:3674-3681.
27. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992;12:1-12.
28. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994;86:1159-1166.
29. Barth RJ Jr, Mulé JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991;173:647-658.
30. Schwartzentruber DJ, Hom SS, Dadmarz R et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12: 1475-1483.
31. Kooi S, Freedman RS, Rodriguez-Villanueva J, Platsoucas CD. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res 1993;12:429-437.
32. Torsteinsdottir S, Masucci MG, Brautbar C, Lenoir G, Klein G, Klein E. Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones. Cell Immunol 1986;98:453-466.